Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![AcumenPharm Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1440022980487225348.png) Acumen Pharmaceuticals, Inc. [@AcumenPharm](/creator/twitter/AcumenPharm) on x XXX followers
Created: 2025-07-17 13:52:00 UTC

Exciting news from Acumen: We’ve entered a strategic collaboration, option, and license agreement with JCR Pharmaceuticals to develop a novel Alzheimer’s therapy using their proprietary J-Brain Cargo® platform.

Learn more in our joint press release:

![](https://pbs.twimg.com/media/GwEGtHMXUAAWnPW.jpg)

XX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1945843933474357630/c:line.svg)

**Related Topics**
[alzheimers](/topic/alzheimers)
[$4552t](/topic/$4552t)

[Post Link](https://x.com/AcumenPharm/status/1945843933474357630)

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

AcumenPharm Avatar Acumen Pharmaceuticals, Inc. @AcumenPharm on x XXX followers Created: 2025-07-17 13:52:00 UTC

Exciting news from Acumen: We’ve entered a strategic collaboration, option, and license agreement with JCR Pharmaceuticals to develop a novel Alzheimer’s therapy using their proprietary J-Brain Cargo® platform.

Learn more in our joint press release:

XX engagements

Engagements Line Chart

Related Topics alzheimers $4552t

Post Link

post/tweet::1945843933474357630
/post/tweet::1945843933474357630